Restylane Silk Microinjections to Cheeks

Goldman, Butterwick, Fitzpatrick and Groff20 enrolled

Overview

The objective of this study is to determine the efficacy and safety of Restylane® Silk microinjections when used in a grid-like injection pattern for the correction of fine lines to the cheeks.

Silk for correction of mid to low cheek fine lines and wrinkles. Twenty (20) subjects will be enrolled. Each subject will receive Restylane® Silk to the entire cheeks. The defined area will be defined as the following: line extending from the upper margin of the nasal ala to the upper margin of the tragus, from the tragus to 1 cm above the mandibular angle, from 1 cm above the mandibular angle to 1 cm above the pre-jowl sulcus, and from 1 cm above the pre-jowl sulcus to the upper margin of the nasal ala. The injections will be delivered intradermally via multiple 0.02 cc microinjections distributed in a grid array pattern with 1-2 cm between each injection point (see figure 1; injections will extend 1 cm above the illustration). Following completion of injection treatment, manual massage will be applied to the full area to promote even distribution of the product. Each subject will undergo a total of three treatment sessions, one month apart, day 1, week 4, and week 8. The maximum amount of Restylane to be used per treatments session/per cheek is 1.5cc (not to exceed a total of 9 cc) per treated patient. Three-dimensional digital photography utilizing the Vectra 3D System (Canfield) will be utilized to document pre-treatment status, sites of injection, and post-treatment effect. Subjects will be followed up at 4 weeks, 8 weeks, post-treatment day 90, and day 180. Objective measures of efficacy will be me performed pre-treatment, at day 90 and 180.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Wrinkle

Interventions

Restylane® SilkDEVICE

Injectable Hyaluronic Acid (HA)

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: b. Symmetrical visible sign of aging involving at least a 9 cm2 area of the mid to low cheeks. c. Must be willing to give and sign a HIPPA form, photo consent and informed consent form. d. Must be willing to comply with study dosing and complete the entire course of the study. e. Female patients will be either of non-childbearing potential defined as: 1\. Having no uterus 2. No menses for at least 12 months. Or; (WOCBP) women of childbearing potential must agree to use an effective method of birth control during the course of the study, such as: 1. Oral contraceptive pill, injection, implant, patch, vaginal ring, intrauterine device 2. Intrauterine coil 3. Bilateral tubal ligation 4. Barrier method used with an additional form of contraception (e.g., sponge, spermicide or condom) 5. Abstinence (If practicing abstinence must agree to use barrier method described above (4) if becomes sexually active). 6. Vasectomized partner (must agree to use barrier method described above (4) if becomes sexually active with un-vasectomized). f. Negative urine pregnancy test results Baseline prior to study entry (if applicable) Exclusion Criteria: 1. Pregnant, planning pregnancy during the course of the study or breastfeeding 2. Extremely Severe aging face with extensive photodamage 3. Previous use of any form of soft tissue augmentation in the treatment area within the past 12 months 4. Pre-existing medical or dermatologic condition in the treatment area that may affect the treatment or interpretation of treatment effect (at investigator discretion) 5. Presence of tattoo and/or scar in the treatment area that in the investigators opinion would interfere with study assessments 6. Use of oral/topical retinoids within 1 month of Baseline 7. Previous use of botulinum toxins in the treatment area within the past 6 months 8. Previous surgical procedure in the treatment area within the past 12 months 9. Presence or evidence of any conditions that in the opinion of the investigator might impede the subject's ability to give consent or comply with protocol requirements. 10. Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study 11. History of non-compliance with clinical research protocols 12. Ablative laser resurfacing to on their face within 12 months 13. Non-ablative laser or light procedures to their face within the past 3 months 14. Known allergy to Restylane® Silk or any of its constituents

Locations (1)

West Dermatology Research Center

San Diego, California, United States

RECRUITING

Outcomes

Primary Outcomes

Investigator five point global aesthetic improvement score

Change in Investigator five point global aesthetic improvement score from Baseline at all follow up visits through month 6 using Investogator's Global Aesthetic Improvement Scale

Time frame: Baseline to 6 - Months Post Final Treatment

Cutometer Measured Skin Elaticity

Change in elasticity from baseline to the last visit measured using a Cutometer

Time frame: Baseline to 6 - Months Post Final Treatment

Hydrometer measured Transepidermal Water Loss

Change in transepidermal waterloss from baseline to the last visit measured using a hydrometer.

Time frame: Baseline to 6 - Months Post Final Treatment

Secondary Outcomes

Safety - Injection Site Adverse Events

At each follow up visit, any adverse effects such as but not limited to bruising, erythema, swelling, pain, tenderness, itching, dysesthesia, and nodularity will be recorded descriptively.

Time frame: Baseline to 6 - Months Post Final Treatment

Central Contacts

Shannon Quigley

CONTACT

858 657 1004 SQuigley@CLDerm.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.